4192 Stock Overview
Engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SynCore Biotechnology Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$35.85 |
| 52 Week High | NT$57.80 |
| 52 Week Low | NT$34.55 |
| Beta | 1.04 |
| 11 Month Change | -2.71% |
| 3 Month Change | -9.47% |
| 1 Year Change | -2.98% |
| 33 Year Change | -70.58% |
| 5 Year Change | -67.97% |
| Change since IPO | -91.81% |
Recent News & Updates
Shareholder Returns
| 4192 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.0% | 0.7% | -1.4% |
| 1Y | -3.0% | 6.8% | 26.5% |
Return vs Industry: 4192 underperformed the TW Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: 4192 underperformed the TW Market which returned 28.7% over the past year.
Price Volatility
| 4192 volatility | |
|---|---|
| 4192 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4192 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4192's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 40 | Muh-Hwan Su | www.syncorebio.com |
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials.
SynCore Biotechnology Co.,Ltd Fundamentals Summary
| 4192 fundamental statistics | |
|---|---|
| Market cap | NT$1.26b |
| Earnings (TTM) | NT$364.00k |
| Revenue (TTM) | NT$22.93m |
3,463x
P/E Ratio55.0x
P/S RatioIs 4192 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4192 income statement (TTM) | |
|---|---|
| Revenue | NT$22.93m |
| Cost of Revenue | NT$21.15m |
| Gross Profit | NT$1.78m |
| Other Expenses | NT$1.41m |
| Earnings | NT$364.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.01 |
| Gross Margin | 7.75% |
| Net Profit Margin | 1.59% |
| Debt/Equity Ratio | 0% |
How did 4192 perform over the long term?
See historical performance and comparison